Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Mol Pharm ; 20(5): 2589-2599, 2023 05 01.
Artigo em Inglês | MEDLINE | ID: mdl-37037186

RESUMO

Encorafenib is a kinase inhibitor indicated for the treatment of patients with BRAF mutant melanoma and BRAF mutant metastatic colorectal cancer. To understand the effect of food and coadministration with a proton-pump inhibitor (PPI), in vitro, in vivo, and in silico data were generated to optimize the clinical dose, evaluate safety, and better understand the oral absorption process under these conditions. Study 1 evaluated the effect of food on the plasma pharmacokinetics, safety, and tolerability after a single oral dose of encorafenib 100 mg. Study 2 evaluated the same end points with coadministration of encorafenib and rabeprazole (PPI perpetrator). The in vitro gastrointestinal TIM-1 model was used to investigate the release of encorafenib and the amount available for absorption under different testing conditions (fasted, fed, and with the use of a PPI). The fasted, fed, and PPI states were predicted for the encorafenib commercial capsule in GastroPlus 9.8. In study 1, both AUCinf and AUClast decreased by 4% with the administration of a high-fat meal. The Cmax was 36% lower than with fasted conditions. All 3 exposure parameters in study 2 (AUCinf, AUClast, and Cmax) had mean changes of <10% when encorafenib was coadministered with a PPI. Using the in vitro gastrointestinal simulator TIM-1, the model demonstrated a similar release of drug, as the bioaccessible fraction, in the 3 conditions was equal (≥80%), predicting no PPI or food effect for this drug formulation. The modeling in GastroPlus 9.8 demonstrated complete absorption of encorafenib when formulated as an amorphous solid dispersion. To obtain these results, it was crucial to integrate the amorphous solubility of the drug that shows a 20-fold higher solubility at pH 6.8 compared with crystalline solubility. The increased amorphous solubility is likely the reason no PPI effect was observed compared with fasted state conditions. The prolongation in gastric emptying in the fed state resulted in delayed plasma Tmax for encorafenib. No dose adjustment is necessary when encorafenib is administered in the fed state or when coadministered with a PPI. Both the TIM-1 and physiologically based pharmacokinetic model results were consistent with the observed clinical data, suggesting that these will be valuable tools for future work.


Assuntos
Proteínas Proto-Oncogênicas B-raf , Inibidores da Bomba de Prótons , Humanos , Inibidores da Bomba de Prótons/farmacocinética , Administração Oral , Interações Alimento-Droga , Preparações Farmacêuticas , Solubilidade , Estudos Cross-Over , Disponibilidade Biológica
2.
J Vitreoretin Dis ; 7(2): 160-164, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37006669

RESUMO

Purpose: To describe a 90-year-old patient who was referred to a private retina specialist with gradually worsening vision and floaters in the left eye. Methods: A retrospective case report is presented. Results: The patient was treated with intravitreal rituximab injections for intraocular lymphoma with resulting vision loss to the level of hand motions from severe granulomatous uveitis and retinal occlusive vasculitis. Conclusions: Retinal occlusive vasculopathy secondary to rituximab intravitreal injections is a rare clinical entity with only a single previous case reported in the literature. However, there are reports of systemic vasculitis after systemic administration of rituximab. Clinicians should be aware of the possibility of ocular hypertension, granulomatous anterior uveitis, and/or retinal occlusive vasculitis after intravitreal rituximab use. Consideration should be given to the inflammatory risk of rituximab intravitreal injections to reduce the potential for treatment-induced vision loss.

3.
Can Urol Assoc J ; 17(6): 176-182, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-36952302

RESUMO

INTRODUCTION: Most centers have shifted to an extended day surgery (XDS ) model for urethroplasty. Our study characterizes outcomes and unplanned healthcare encounters of patients undergoing XDS urethroplasty compared to case-matched inpatient controls. METHODS: We conducted a retrospective, two-surgeon, single-center study of patients undergoing XDS urethroplasty (discharge <24 hrs) from November 2020 to November 2021. Patients were case-control matched based on age, stricture length, location, and etiology to patients who had previously undergone inpatient urethroplasty. Data was analyzed using descriptive and univariable statistics. Multivariable analysis by Cox proportional hazard regression was used to identify associations with postoperative complications. RESULTS: Ninety patients (mean age=53.8 years) underwent XDS urethroplasty during the study period. Mean stricture length was 4.4 cm (standard deviation [SD ] 2.4). Rates of postoperative complications were similar between XDS (17%, n=15) and admitted patients (21%, n=19), and XDS was not associated with increased risk on univariable analysis (odds ratio [OR ] 0.65, 95% confidence interval [CI] 0.31-1.3, p=0.36). When stratifying by location, penile stricture (OR 4.21, 95% CI 1.3-13.8, p=0.02) and lichen sclerosus (OR 2.91, 95% CI 0.79-9.9, p=0.08) were associated with increased risk of postoperative complication. On multivariable analysis, only penile stricture was identified as significant (OR 4.78, 95% CI 1.2-19.4, p=0.03). Forty-eight percent (n=43) of patients had unplanned healthcare encounters postoperatively, with similar numbers of phone calls (n=37) and emergency department visits (n=36) between groups. CONCLUSIONS: Our study shows that XDS urethroplasty is not associated with increased rates of complications relative to inpatient admission. This data supports using an XDS pathway for resource-efficient treatment of urethral strictures in a universal healthcare setting.

4.
Mol Pharm ; 18(4): 1530-1543, 2021 04 05.
Artigo em Inglês | MEDLINE | ID: mdl-33656882

RESUMO

The aim of the study was to investigate the impact of Crohn's disease (CD) on the performance of a lipid-based formulation of ciprofloxacin in a complex gastrointestinal simulator (TIM-1, TNO) and to compare the luminal environment in terms of bile salt and lipid composition in CD and healthy conditions. CD conditions were simulated in the TIM-1 system with a reduced concentration of porcine pancreatin and porcine bile. The bioaccessibility of ciprofloxacin was similar in simulated CD and healthy conditions considering its extent as well as its time course in the jejunum and ileum filtrate. Differences were observed in terms of the luminal concentration of triglycerides, monoglycerides, and fatty acids in the different TIM-1 compartments, indicating a reduction and delay in the lipolysis of formulation excipients in CD. The quantitative analysis of bile salts revealed higher concentrations for healthy conditions (standard TIM-1 fasted-state protocol) in the duodenum and jejunum TIM-1 compartments compared to published data in human intestinal fluids of healthy subjects. The reduced concentrations of bile salts in simulated CD conditions correspond to the levels observed in human intestinal fluids of healthy subjects in the fasted state.A lipidomics approach with ultra performance liquid chromatography (UPLC)/mass spectrometry (MS) has proven to be a time-efficient method to semiquantitatively analyze differences in fatty acid and bile salt levels between healthy and CD conditions. The dynamic luminal environment in CD and healthy conditions after administration of a lipid-based formulation can be simulated using the TIM-1 system. For ciprofloxacin, an altered luminal lipid composition had no impact on its performance indicating a low risk of altered performance in CD patients.


Assuntos
Ciprofloxacina/farmacocinética , Doença de Crohn/tratamento farmacológico , Excipientes/química , Mucosa Intestinal/metabolismo , Lipídeos/química , Administração Oral , Animais , Ácidos e Sais Biliares/metabolismo , Ciprofloxacina/administração & dosagem , Doença de Crohn/patologia , Jejum , Voluntários Saudáveis , Humanos , Íleo/metabolismo , Íleo/patologia , Mucosa Intestinal/patologia , Jejuno/metabolismo , Jejuno/patologia , Lipidômica , Pancreatina/metabolismo , Suspensões , Suínos , Distribuição Tecidual
5.
Eur J Pharm Sci ; 157: 105617, 2021 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-33164838

RESUMO

OBJECTIVES: Drug product performance might be affected in Crohn's disease (CD) patients compared to healthy subjects due to pathophysiological changes. Since a low number of clinical studies is performed in this patient population, physiologically-based pharmacokinetic (PBPK) models with integrated results from biorelevant in vitro dissolution studies could be used to assess differences in the bioavailability of drugs. Using this approach, budesonide was used as model drug and its performance in healthy subjects and CD patients was predicted and compared against observed pharmacokinetic data. The in vitro release tests, under healthy versus CD conditions, revealed a similar extent of drug release from a controlled-release budesonide formulation in the fasted state, whereas in the fed state a lower extent was observed with CD. Differences in the physiology of CD patients were identified in literature and their impact on budesonide performance was investigated with a PBPK model, revealing the highest impact on the simulated bioavailability for the reduced hepatic CYP3A4 enzyme abundance and lower human serum albumin concentration. For CD patients, a higher budesonide exposure compared to healthy subjects was predicted with a PBPK population adapted to CD physiology and in agreement with observed pharmacokinetic data. Budesonide performance in the fasted and fed state was successfully predicted in healthy subjects and CD patients using PBPK modeling and in vitro release testing. Following this approach, predictions of the direction and magnitude of changes in bioavailability due to CD could be made for other drugs and guide prescribers to adjust dosage regimens for CD patients accordingly.


Assuntos
Doença de Crohn , Budesonida , Simulação por Computador , Doença de Crohn/tratamento farmacológico , Voluntários Saudáveis , Humanos , Modelos Biológicos , Solubilidade
6.
Eur J Pharm Sci ; 152: 105459, 2020 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-32649984

RESUMO

In order to investigate differences in drug solubilisation and dissolution in luminal fluids of Crohn's disease (CD) patients and healthy subjects, biorelevant media representative of CD patients were developed using information from literature and a Design of Experiment (DoE) approach. The CD media were characterised in terms of surface tension, osmolality, dynamic viscosity and buffer capacity and compared to healthy biorelevant media. To identify which drug characteristics are likely to present a high risk of altered drug solubility in CD, the solubility of six drugs was assessed in CD media and solubility differences were related to drug properties. Identified differences in CD patients compared to healthy subjects were a reduced concentration of bile salts, a higher gastric pH and a higher colonic osmolality. Differences in the properties of CD compared to healthy biorelevant media were mainly observed for surface tension and osmolality. Drug solubility of ionisable compounds was altered in gastric CD media compared to healthy biorelevant media. For drugs with moderate to high lipophilicity, a high risk of altered drug solubilisation in CD is expected, since a significant negative effect of log P and a positive effect of bile salts on drug solubility in colonic and fasted state intestinal CD media was observed. Simulating the conditions in CD patients in vitro offers the possibility to identify relevant differences in drug solubilisation without conducting expensive clinical trials.


Assuntos
Doença de Crohn , Preparações Farmacêuticas , Doença de Crohn/tratamento farmacológico , Humanos , Concentração de Íons de Hidrogênio , Concentração Osmolar , Solubilidade
7.
Toxicol In Vitro ; 66: 104875, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32339640

RESUMO

The focus of the present study was to examine the acute immunotoxic properties of oil sands process-affected waters (OSPW) using the RAW 264.7 macrophage cell line. Specifically, we used a quantitative PCR assay to monitor changes in the expression of stress, cytokine, and antimicrobial enzyme genes in activated macrophages following acute (i.e. < 24 h) exposure of the cells to whole OSPW and its fractions. Overall, our data shows that OSPW inorganic fraction (IF) significantly induces the expression of genes associated with oxidative stress and DNA damage and that the OSPW-IF also significantly augmented cytokine gene expression. These effects are similar to what was observed following whole OSPW exposures, which contrasts the minimal effects observed when cells were treated with equivalent doses of the OSPW organic fraction (OF). Surprisingly, OSPW-IF had reciprocal effects on gene and protein expression levels of two key macrophage enzymes (e.g. inducible nitric oxide (iNOS) synthase and arginase), which indicates that components within OSPW-IF have the unique ability to alter the overall functional states of macrophage by polarizing them towards an alternatively activated status; concomitant with the reciprocal depression of iNOS levels and enhanced expression and activity of arginase. Collectively, these findings show that at sub-lethal exposure doses, the inorganic constituents of OSPW have significant immunotoxicological properties that could potentially affect innate cellular defense responses of exposed animals.


Assuntos
Resíduos Industriais/efeitos adversos , Campos de Petróleo e Gás , Águas Residuárias/toxicidade , Poluentes Químicos da Água/toxicidade , Animais , Arginase/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Dano ao DNA , Expressão Gênica/efeitos dos fármacos , Imunidade Inata/efeitos dos fármacos , Camundongos , Óxido Nítrico Sintase Tipo II/genética , Óxido Nítrico Sintase Tipo II/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Células RAW 264.7
8.
Parasitol Res ; 118(4): 1147-1158, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-30747294

RESUMO

Trypanosoma carassii is a flagellated bloodstream parasite of cyprinid fish with pathogenesis manifesting primarily as anemia in experimentally infected fish. This anemia is characterized by decreases in the number of circulating red blood cells (RBCs) during peak parasitemia. We examined changes in the key blood metrics and expression of genes known to be important in the regulation of erythropoiesis. Increasing parasitemia was strongly correlated with an overall decrease in the total number of circulating RBCs. Gene expression of key erythropoiesis regulators (EPO, EPOR, GATA1, Lmo2, and HIFα) and proinflammatory cytokines (IFNγ and TNFα) were measured and their expressions differed from those in fish made anemic by injections of phenylhydrazine (PHZ). Significant upregulation of pro-erythropoietic genes was observed in PHZ-induced anemia, but not during peak parasitic infection. Previously, we reported on functional characterization of goldfish erythropoietin (rgEPO) and its ability to induce survival and differentiation of erythroid progenitor cells in vitro. Treatment of goldfish during the infection with rgEPO reduced the severity of anemia but failed to fully prevent the onset of the anemic state in infected fish. Proinflammatory cytokines have been implicated in the suppression of erythropoiesis during trypanosomiasis, specifically the cytokines TNFα, IFNγ, and IL-1ß. Analysis of key proinflammatory cytokines revealed that mRNA levels of IFNγ and TNFα were upregulated in response to infection, but only TNFα increased in response to PHZ treatment. Synergistic activity of the proinflammatory cytokines may be required to sustain prolonged anemia. These findings provide insight into the relationship between T. carassii and host anemia and suggest that T. carassii may directly or indirectly suppress host erythropoiesis.


Assuntos
Anemia/genética , Citocinas/biossíntese , Eritropoese/genética , Regulação da Expressão Gênica/genética , Carpa Dourada/parasitologia , Parasitemia/patologia , Trypanosoma/classificação , Anemia/parasitologia , Animais , Contagem de Eritrócitos , Eritropoetina/biossíntese , Fator de Transcrição GATA1/biossíntese , Interferon gama/biossíntese , Proteínas com Domínio LIM/biossíntese , Fenil-Hidrazinas/farmacologia , RNA Mensageiro/genética , Receptores da Eritropoetina/biossíntese , Tripanossomíase/patologia , Fator de Necrose Tumoral alfa/biossíntese
9.
Dev Comp Immunol ; 94: 11-15, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-30659854

RESUMO

Hepcidin is an antimicrobial peptide and an iron regulatory protein that prevents the release of excess iron in the blood. There is evidence suggesting that teleost hepcidin is a major player in antimicrobial defense against various bacteria species, but little is known regarding the effects of teleost hepcidin in protozoan parasitic infections. We examined the role of hepcidin during the course of infection of goldfish with Trypanosoma carassii. Quantitative real-time PCR was used to determine the expression of hepcidin in goldfish immune organs during the course of T. carassii infection. During the acute phase of the T. carassii infection, the mRNA levels of hepcidin were up-regulated in liver and kidney. In contrast, an up-regulation of hepcidin mRNA expression in spleen was observed during the chronic phase of the infection. Furthermore, a synthetic goldfish hepcidin peptide induced trypanosome lysis in vitro, and parasite surface disruption was confirmed by scanning electron microscopy (SEM) analysis. These results suggest that, in addition to well-characterized direct antibacterial activities, teleost hepcidin also exhibits trypanocidal activity.


Assuntos
Anti-Infecciosos/metabolismo , Doenças dos Peixes/imunologia , Carpa Dourada/imunologia , Hepcidinas/metabolismo , Macrófagos/imunologia , Trypanosoma/imunologia , Tripanossomíase/imunologia , Animais , Citocinas/metabolismo , Imunidade Inata , Transcriptoma , Regulação para Cima
10.
Obes Surg ; 19(12): 1719-23, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19184614

RESUMO

Intussusception is an atypical cause of small bowel obstruction following Roux-en-Y gastric bypass and, as such, is not often considered in the differential diagnosis. In this setting, the pathophysiology appears to differ in that a pathologic lead point is rarely identified and the intussusceptum most often progresses retrograde into the proximal bowel. Involvement of the jejunojejunostomy is nearly universal in reported cases and, if untreated, can lead to devastating consequences. Despite this potential, the clinical presentation often lacks remarkable features yet timely surgical intervention is generally required. This phenomenon is being reported with greater frequency and altered motility in the Roux limb is the prevailing hypothesis regarding pathogenesis. Awareness of the potential for this process and prompt consultation with a bariatric surgeon are keys to optimal outcomes.


Assuntos
Derivação Gástrica/efeitos adversos , Gastroplastia/efeitos adversos , Intussuscepção/etiologia , Doenças do Jejuno/etiologia , Jejuno/cirurgia , Humanos , Intussuscepção/patologia , Intussuscepção/cirurgia , Doenças do Jejuno/patologia , Doenças do Jejuno/cirurgia , Jejuno/patologia , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
11.
J Psychoactive Drugs ; 40(2): 211-4, 2008 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-18720672

RESUMO

Chloroquine and its derivatives have been drugs of choice in the prophylaxis and treatment of malaria for over 50 years. These drugs are also frequently used in the treatment of various rheumatologic disorders. Because many Americans now travel abroad and may require chloroquine prophylaxis, as well as the fact that such medications are readily available through Internet-based supply houses, clinicians should be aware of the potential toxicity associated with the use of these agents. We present the case of an adolescent female who presented with acute, chloroquine-induced toxic psychosis resembling that induced by phencyclidine (PCP) in clinical presentation and laboratory findings. In the acute setting, the differentiation between chloroquine toxic psychosis and PCP psychosis may be difficult. Therefore, the syndrome of chloroquine-induced psychosis is reviewed and its differentiation from PCP psychosis highlighted as it relates to important aspects of this case.


Assuntos
Antimaláricos/toxicidade , Cloroquina/toxicidade , Hidroxicloroquina/uso terapêutico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Erros de Medicação , Abuso de Fenciclidina/diagnóstico , Psicoses Induzidas por Substâncias/diagnóstico , Adolescente , Antimaláricos/uso terapêutico , Catatonia/induzido quimicamente , Catatonia/diagnóstico , Catatonia/psicologia , Cloroquina/uso terapêutico , Diagnóstico Diferencial , Feminino , Humanos , Fenciclidina/urina , Abuso de Fenciclidina/psicologia , Abuso de Fenciclidina/urina , Psicoses Induzidas por Substâncias/psicologia , Psicoses Induzidas por Substâncias/urina , Detecção do Abuso de Substâncias
12.
Brain Res ; 951(2): 243-54, 2002 Oct 04.
Artigo em Inglês | MEDLINE | ID: mdl-12270503

RESUMO

Blood-brain barrier endothelial cells are characterized by the presence of tight intercellular junctions, the absence of fenestrations, and a paucity of pinocytotic vesicles. The in vitro study of the BBB has progressed rapidly over the past several years as new cell culture techniques and improved technologies to monitor BBB function became available. Studies carried out on viable in vitro models are set to accelerate the design of drugs that selectively and aggressively can target the CNS. Several systems in vitro attempt to reproduce the physical and biochemical behavior of intact BBB, but most fail to reproduce the three-dimensional nature of the in vivo barrier and do not allow concomitant exposure of endothelial cells to abluminal (glia) and lumenal (flow) influences. For this purpose, we have developed a new dynamic in vitro BBB model (NDIV-BBB) designed to allow for extensive pharmacological, morphological and physiological studies. Bovine aortic endothelial cells (BAEC) developed robust growth and differentiation when co-cultured alone. In the presence of glial cells, BAEC developed elevated Trans-Endothelial Electrical Resistance (TEER). Excision of individual capillaries proportionally decreased TEER; the remaining bundles were populated with healthy cells. Flow played an essential role in EC differentiation by decreasing cell division. In conclusion, this new dynamic model of the BBB allows for longitudinal studies of the effects of flow and co-culture in a controlled and fully recyclable environment that also permits visual inspection of the abluminal compartment and manipulation of individual capillaries.


Assuntos
Astrócitos/fisiologia , Barreira Hematoencefálica/fisiologia , Endotélio Vascular/citologia , Endotélio Vascular/fisiologia , Algoritmos , Animais , Aorta/citologia , Neoplasias Encefálicas/patologia , Capilares/fisiologia , Capilares/ultraestrutura , Bovinos , Circulação Cerebrovascular/fisiologia , Técnicas de Cocultura/métodos , Técnicas Citológicas , Glioma/patologia , Glucose/metabolismo , Ácido Láctico/biossíntese , Fibras Minerais , Modelos Neurológicos , Fibras Nervosas/fisiologia , Fibras Nervosas/ultraestrutura , Pressão , Ratos , Células Tumorais Cultivadas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA